A phase IIa, open-label, single-arm, two stage, multi-centre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of repeated subcutaneous administration of BIM23B065 in subjects with acromegaly

Trial Profile

A phase IIa, open-label, single-arm, two stage, multi-centre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of repeated subcutaneous administration of BIM23B065 in subjects with acromegaly

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs BIM 23B065 (Primary)
  • Indications Acromegaly
  • Focus Pharmacodynamics
  • Sponsors Ipsen
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to discontinued as per sponsor decision. No new safety signal or serious adverse event has been observed.
    • 23 Jun 2017 This trial has been discontinued in Hungary.
    • 17 Jun 2017 This trial has been discontinued in Bulgaria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top